• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marpai Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    5/24/24 4:05:34 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    8-K
    false000184439200018443922024-05-242024-05-24

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 24, 2024

     

     

    MARPAI, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40904

    86-1916231

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    615 Channelside Drive, Suite 207

     

    Tampa, Florida

     

    33602

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 855 389-7330

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, par value $0.0001 per share

     

    MRAI

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On May 24, 2024, Marpai, Inc. (the “Company”) informed the staff of the Nasdaq Stock Market LLC of its intention to withdraw from the Nasdaq hearings process and transition the listing of its Class A common shares, par value $0.0001 per share (the “Shares”), from the Nasdaq Capital Market (“Nasdaq”) and have the Shares quoted on the OTCQX Market (“OTCQX”). The Company was under a Nasdaq Panel Monitor and was not in compliance with the minimum stockholders’ equity requirement, as outlined in Nasdaq Listing Rule 5550(b)(1). The Company expects that its Shares will be suspended from trading on Nasdaq effective at the opening of trading on Wednesday, May 29, 2024, and will have its Shares commence trading on OTCQX immediately thereafter. The Company anticipates that the Nasdaq hearings panel will file a Form 25 with the Securities and Exchange Commission which will formally delist the Company’s Shares from Nasdaq in the near term.

    The Company will remain subject to the periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended, following the delisting of its Shares from Nasdaq.

    The Company’s delisting is expected to reduce the Company’s costs as it advances its strategy to drive profitable growth. The Company intends to have its Shares quoted on OTCQX and expects that the Shares will be traded on OTCQX under its current trading symbol “MRAI” concurrent with the Nasdaq trading suspension. The Company expects that transferring its Shares to OTCQX will ensure that a trading market may continue to exist for such securities. There is no guarantee, however, that a broker will continue to make a market in the Shares or that trading thereof will continue on OTCQX or otherwise.

    Item 7.01 Regulation FD Disclosure.

    As disclosed above, on May 24, 2024, the Company issued a press release announcing withdrawal from the Nasdaq hearings process and the transition of its trading to OTCQX. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number

    Description

    99.1

    Press release of Marpai, Inc. dated May 24, 2024

    104

    Cover Page Interactive Data File (embedded within Inline XBRL document)

     

    Forward-Looking Statements

    The information contained herein includes forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “will likely result,” and similar expressions. These statements relate to future events or to our strategies, targeted markets, and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and those discussed in other documents we file with the SEC, including, the timing of the effectiveness of our delisting, the timing of our listing on OTCQX, and that as a result of the delisting, we expect to reduce our costs as we advance our strategy to drive profitable growth. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future, unless required by law. The safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of such Act.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    MARPAI, INC.

     

     

     

     

    Date:

    May 24, 2024

    By:

    /s/ Damien Lamendola

     

     

     

    Name: Damien Lamendola
    Title: Chief Executive Officer

     


    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    SEC Filings

    View All

    SEC Form 10-K filed by Marpai Inc.

    10-K - Marpai, Inc. (0001844392) (Filer)

    3/25/26 4:44:45 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    3/11/26 8:28:32 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    2/27/26 10:13:31 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marpai, Inc. Secures Major Strategic Marketing Collaboration to Continue Acceleration of MarpaiRx Growth Nationwide

    TAMPA, Fla., April 1, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced the execution of what the Company believes is its largest to date definitive marketing agreement with a leading healthcare solutions provider. This strategic collaboration is designed to scale the reach of MarpaiRx, Marpai's pharmacy benefit management (PBM) services, across a vast network of self-insured employer groups and third-party administrators.Under the terms of the three-year agreement, the team will leverage its extensive domestic and internati

    4/1/26 12:23:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Secures Access to Network Creating Major Growth Catalyst for MarpaiRx Representing Up to 1.5 million Covered Lives

    Marketing Agreement Establishes Powerful National Distribution Channel and Expands Marpai's Revenue Growth OpportunityTAMPA, Fla., March 9, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced the execution of a transformational marketing agreement dramatically expanding the national reach of its high-growth pharmacy benefit management division, providing access to a network representing up to 1.5 million covered employees for MarpaiRx.The agreement creates a powerful new distribution channel for MarpaiRx's pharmacy benefit sol

    3/9/26 8:08:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform Expansion

    New Client Momentum Highlights Rapid Adoption of Marpai's Disruptive, Scalable Healthcare Platform Positioned to Drive Exponential Revenue Growth and Long-Term Shareholder ValueTAMPA, Fla., Feb. 23, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management (PBM) services, today announced two significant strategic client wins for its high-growth MarpaiRx division, adding more than 19,000 covered lives and further accelerating the Company's expansion as a next-generation healthcare platform.We believe that these wins represent strong validation of Marpai's different

    2/23/26 8:08:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Scrip Dallas was granted 100,000 shares (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:48:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

    STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

    1/22/25 5:00:00 PM ET
    $HIT
    $MRAI
    Specialty Insurers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care